Human regulatory T cells lack the cyclophosphamideextruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis

European Journal of Immunology

Volumn 44, Issue 12, 2014, Pages 3614-3620

  Dimeloe, Sarah ^a   Frick, Corina ^a   Fischer, Marco ^a   Gubser, Patrick M ^a   Razik, Leyla ^a   Bantug, Glenn R ^a   Ravon, Morgane ^b   Langenkamp, Anja ^b   Hess, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

CD4+ T cells; Clinical Immunology; Cyclophosphamide; Cytotoxicity; Pharmacology; Regulatory T cells

Indexed keywords

BETA ACTIN; CYCLOPHOSPHAMIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; VERAPAMIL; ABCB1 PROTEIN, HUMAN; ALKYLATING AGENT; CYTOTOXIN; MULTIDRUG RESISTANCE PROTEIN;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; CLINICAL TRIAL; CYTOLOGY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MALE; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CYCLOPHOSPHAMIDE; CYTOTOXINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTE DEPLETION; MALE; NEOPLASMS; P-GLYCOPROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 84924292037     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444879     Document Type: Article

References (25)

1. Brayboy, L. M., Oulhen, N., Witmyer, J., Robins, J., Carson, S. and Wessel, G. M., Multidrug-resistant transport activity protects oocytes from chemotherapeutic agents and changes during oocyte maturation. Fertil. Steril. 2013. 100: 1428-1435.
2. Patutina, O. A., Mironova, N. L., Popova, N. A., Kaledin, V. I., Nikolin, V. P., Vlassov, V. V. and Zenkova, M. A., The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer 2010. 10: 204.
3. Patutina, O. A., Mironova, N. L., Logashenko, E. B., Popova, N. A., Nikolin, V. P., Vasil'ev, G. V., Kaledin, V. I. et al., Cyclophosphamide metabolite inducing apoptosis in RLS mouse lymphosarcoma cells is a substrate for P-glycoprotein. Bull. Exp. Biol. Med. 2012. 152: 348-352.
4. Schinkel, A. H. and Jonker, J.W., Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003. 55: 3-29.
5. Neyfakh, A. A., Serpinskaya, A. S., Chervonsky, A. V., Apasov, S. G. and Kazarov, A. R., Multidrug-resistance phenotype of a subpopulation of T-lymphocytes without drug selection. Exp. Cell Res. 1989. 185: 496-505.
6. Chaudhary, P. M. and Roninson, I. B., Expression and activity of Pglycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991. 66: 85-94.
7. Chaudhary, P. M., Mechetner, E. B. and Roninson, I. B., Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992. 80: 2735-2739.
8. Drach, D., Zhao, S., Drach, J., Mahadevia, R., Gattringer, C., Huber, H. and Andreeff, M., Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992. 80: 2729-2734.
9. Turtle, C. J., Swanson, H. M., Fujii, N., Estey, E. H. and Riddell, S. R., A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity 2009. 31: 834-844.
10. Ramesh, R., Kozhaya, L., McKevitt, K., Djuretic, I. M., Carlson, T. J., Quintero, M. A., McCauley, J. L. et al., Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med. 2014. 211: 89-104.
11. Chintamani, Singh, J. P., Mittal, M. K., Saxena, S., Bansal, A., Bhatia, A. and Kulshreshtha, P., Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer-a prospective clinical study. World J. Surg. Oncol. 2005. 3: 61.
12. Bray, J., Sludden, J., Griffin, M. J., Cole, M., Verrill, M., Jamieson, D. and Boddy, A. V., Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br. J. Cancer. 2010. 102: 1003-1009.
13. Caronia, D., Patino-Garcia, A., Perez-Martinez, A., Pita, G., Moreno, L. T., Zalacain-Diez, M., Molina, B. et al., Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One 2011. 6: e26091.
14. Castano, A. P., Mroz, P., Wu, M. X. and Hamblin, M. R., Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc. Natl. Acad. Sci. USA 2008. 105: 5495-5500.
15. Tongu, M., Harashima, N., Yamada, T., Harada, T. and Harada, M., Immunogenic chemotherapy with cyclophosphamide and doxorubicin against establishedmurine carcinoma. Cancer Immunol. Immunother. 2010. 59: 769-777.
16. Camisaschi, C., Filipazzi, P., Tazzari, M., Casati, C., Beretta, V., Pilla, L., Patuzzo, R. et al., Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol. Immunother. 2013. 62: 897-908.
17. Cerullo, V., Diaconu, I., Kangasniemi, L., Rajecki, M., Escutenaire, S., Koski, A., Romano, V. et al., Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 2011. 19: 1737-1746.
18. Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E. et al., Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007. 56: 641-648.
19. Brode, S., Raine, T., Zaccone, P. and Cooke, A., Cyclophosphamideinduced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 2006. 177: 6603-6612.
20. Audia, S., Nicolas, A., Cathelin, D., Larmonier, N., Ferrand, C., Foucher, P., Fanton, A. et al., Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin. Exp. Immunol. 2007. 150: 523-530.
21. Marques-Santos, L. F., Oliveira, J. G. P., Maia, R. C. and Rumjanek, V. M. Mitotracker green is a P-glycoprotein substrate. Biosci. Rep. 2003. 23: 199-212.
22. Wirths, S. and Lanzavecchia, A., ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells. Eur. J. Immunol. 2005. 35: 3433-3441.
23. Heylmann, D., Bauer, M., Becker, H., van Gool, S., Bacher, N., Steinbrink, K. and Kaina, B., Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response. PLoS One 2013. 8: e83384.
24. Zhao, J., Cao, Y., Lei, Z., Yang, Z., Zhang, B. and Huang, B., Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010. 70: 4850-4858.
25. Kanakry, C. G., Ganguly, S., Zahurak, M., Bolaños-Meade, J., Thoburn, C., Perkins, B., Fuchs, E. J. et al., Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci. Transl. Med. 2013. 5: 211ra157.